United Therapeutics Corporation Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
United Therapeutics Corporation (UTHR) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $359.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-25
- United Therapeutics Corporation effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $359.90M, a 11.36% increase from fiscal 2024.
- United Therapeutics Corporation effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was $323.20M, a 20.78% increase from fiscal 2023.
- United Therapeutics Corporation effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was $267.60M, a 34.07% increase from fiscal 2022.
- United Therapeutics Corporation effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was $199.60M, a 60.06% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $359.90M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $323.20M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $267.60M 10-K · filed 2026-02-25 | |
| 2022-12-31 | $199.60M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $124.70M 10-K · filed 2024-02-21 | |
| 2020-12-31 | $134.20M 10-K · filed 2023-02-22 | |
| 2019-12-31 | -$34.70M 10-K · filed 2022-02-24 | |
| 2018-12-31 | $159.40M 10-K · filed 2021-02-24 | |
| 2017-12-31 | $269.20M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $371.10M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $365.50M 10-K · filed 2018-02-21 | $365.48M 10-K · filed 2016-02-25 |
| 2014-12-31 | $183.80M 10-K · filed 2017-02-22 | $183.81M 10-K · filed 2015-02-24 |
| 2013-12-31 | $97.62M 10-K · filed 2016-02-25 | |
| 2012-12-31 | $154.24M 10-K · filed 2015-02-24 | |
| 2011-12-31 | $105.02M 10-K · filed 2014-02-25 | |
| 2010-12-31 | $54.30M 10-K · filed 2013-02-26 | |
| 2009-12-31 | $7.74M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |